CN115397421A - 包含tno155和那扎替尼的药物组合 - Google Patents

包含tno155和那扎替尼的药物组合 Download PDF

Info

Publication number
CN115397421A
CN115397421A CN202180028103.7A CN202180028103A CN115397421A CN 115397421 A CN115397421 A CN 115397421A CN 202180028103 A CN202180028103 A CN 202180028103A CN 115397421 A CN115397421 A CN 115397421A
Authority
CN
China
Prior art keywords
day
cancer
egfr
amino
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028103.7A
Other languages
English (en)
Chinese (zh)
Inventor
郝淮湘
刘晨
S·E·穆迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN115397421A publication Critical patent/CN115397421A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180028103.7A 2020-05-08 2021-05-06 包含tno155和那扎替尼的药物组合 Pending CN115397421A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063021772P 2020-05-08 2020-05-08
US63/021,772 2020-05-08
US202063117388P 2020-11-23 2020-11-23
US63/117,388 2020-11-23
PCT/IB2021/053867 WO2021224867A1 (en) 2020-05-08 2021-05-06 Pharmaceutical combination comprising tno155 and nazartinib

Publications (1)

Publication Number Publication Date
CN115397421A true CN115397421A (zh) 2022-11-25

Family

ID=75904981

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028103.7A Pending CN115397421A (zh) 2020-05-08 2021-05-06 包含tno155和那扎替尼的药物组合

Country Status (12)

Country Link
US (1) US20230172928A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146217A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524789A (cg-RX-API-DMAC7.html)
KR (1) KR20230008719A (cg-RX-API-DMAC7.html)
CN (1) CN115397421A (cg-RX-API-DMAC7.html)
AU (1) AU2021267213B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022022305A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179994A1 (cg-RX-API-DMAC7.html)
IL (1) IL297043A (cg-RX-API-DMAC7.html)
MX (1) MX2022013867A (cg-RX-API-DMAC7.html)
TW (1) TW202207933A (cg-RX-API-DMAC7.html)
WO (1) WO2021224867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304526B2 (en) 2018-09-29 2025-05-01 Novartis Ag Production of compounds and preparations for inhibiting the activity of SHP2
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
ES3040751T3 (en) 2020-07-08 2025-11-04 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
AU2022341107A1 (en) 2021-09-08 2024-02-29 Amgen Inc. Sotorasib and an egfr antibody for treating cancer comprising a kras g12c mutation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN110730678B (zh) * 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
EP3856345A1 (en) * 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2

Also Published As

Publication number Publication date
IL297043A (en) 2022-12-01
AU2021267213B2 (en) 2023-11-30
TW202207933A (zh) 2022-03-01
JP2023524789A (ja) 2023-06-13
AU2021267213A1 (en) 2022-11-03
WO2021224867A1 (en) 2021-11-11
US20230172928A1 (en) 2023-06-08
KR20230008719A (ko) 2023-01-16
BR112022022305A2 (pt) 2022-12-20
EP4146217A1 (en) 2023-03-15
CA3179994A1 (en) 2021-11-11
MX2022013867A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
JP7572958B2 (ja) Tno155及びkrasg12c阻害剤を含む医薬組合せ
US12343344B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
CN115297862A (zh) 包含达拉菲尼、erk抑制剂和shp2抑制剂的三重药物组合
EP3442529B1 (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib
HK40004472B (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
HK40004472A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination